01—Abstract
Summary
Summary of the 8-K filed January 5, 2024. Cited figures are marked; the original filing is the authoritative source.
CVS Health's January 5, 2024 8-K reports leadership changes and reaffirms guidance ahead of a January 8, 2024 investor meeting.
Thomas F. Cowhey, who has served as interim CFO since October 13, 2023, was formally appointed Executive Vice President and CFO effective immediately. Shawn M.
Guertin, the prior CFO and President of Health Services, is stepping down for family health reasons and will remain on personal leave until his expected departure on May 31, 2024. Mike Pykosz, CEO of Oak Street Health, was formally named President of Health Care Delivery. For investors, the CFO transition is largely a continuity move, since Cowhey has already overseen investor relations, treasury, and finance operations, but the change still introduces some execution and communication risk during a period of integration.
The company reaffirmed its full-year 2023 guidance: GAAP diluted EPS of $6.37 to $6.61a and Adjusted EPS of $8.50 to $8.70, with Adjusted EPS now expected in the upper half of the range. Cash flow from operations is expected at the upper end of the $12.5 billion to $13.5 billion range. Full-year 2024 guidance was also reaffirmed at GAAP diluted EPS of at least $7.26, Adjusted EPS of at least $8.50, and operating cash flow of at least $12.5 billion.
The company noted that 2023 financial closing procedures are not yet complete, so final results could fall outside the stated ranges. Operationally, management said Medicare Advantage enrollment exceeded expectations during the 2024 annual enrollment period, with a larger-than-historical share of new sales coming from competitor plans.
The company expects total MA membership to grow by at least 800,000 in 2024. Separately, a $3.0 billionb fixed-dollar accelerated share repurchase became effective January 3, 2024, which supports per-share earnings and signals capital return.
02—Key points
Key Highlights
- Thomas F. Cowhey formally appointed EVP and Chief Financial Officer effective January 5, 2024, after serving as interim CFO since October 13, 2023; he receives a $1 million base salary and a 150% target cash incentive plus a $5.5 million target annual equity award.
- Shawn M. Guertin steps down as EVP, CFO and President of Health Services for family health reasons, remaining on personal leave until expected departure on May 31, 2024.
- Full-year 2023 guidance reaffirmed: GAAP diluted EPS of $6.37 to $6.61 and Adjusted EPS of $8.50 to $8.70, with Adjusted EPS expected in the upper half of the range.
- Full-year 2024 guidance reaffirmed: GAAP diluted EPS of at least $7.26, Adjusted EPS of at least $8.50, and cash flow from operations of at least $12.5 billion.
- Medicare Advantage enrollment for 2024 exceeded expectations, with at least 800,000 net membership growth expected, driven by strong new sales and retention of Aetna MA members and a higher share of sales from competitor plans.
- A $3.0 billion fixed-dollar accelerated share repurchase, entered in Q4 2023, became effective January 3, 2024.
- Mike Pykosz, CEO of Oak Street Health, formally named President of Health Care Delivery, tasked with unifying clinic-based and home health assets.
03—Questions
Frequently Asked Questions
Why did the CFO change, and does it signal a problem with the company's finances?
The change was driven by Shawn Guertin's family health situation, not by a disclosed financial problem. Guertin has been on personal leave since October 13, 2023, and the company reaffirmed its guidance alongside the announcement. Tom Cowhey, who has been interim CFO since October and previously oversaw investor relations, treasury and finance operations, is a known internal successor, which points to continuity.
Is CVS still on track to meet its 2023 and 2024 earnings targets?
Management reaffirmed both years' guidance. For 2023, Adjusted EPS is now expected in the upper half of the $8.50 to $8.70 range and operating cash flow at the upper end of $12.5 to $13.5 billion. The company cautioned that 2023 financial closing procedures are incomplete, so final results could fall outside these ranges. The 2024 outlook calls for Adjusted EPS of at least $8.50 and operating cash flow of at least $12.5 billion.
What is driving the expected growth in Medicare Advantage membership?
Management attributed stronger-than-expected 2024 enrollment to Individual MA and dual eligible special needs plan sales exceeding expectations, strong new sales and retention of existing Aetna MA members, and a higher-than-historical share of new sales coming from competitor MA plans. The company expects total MA membership to grow by at least 800,000 in 2024.
How does the $3.0 billion accelerated share repurchase affect shareholders?
The fixed-dollar accelerated share repurchase, entered in Q4 2023 and effective January 3, 2024, returns $3.0 billion to shareholders through immediate share retirement. Reducing the share count supports per-share metrics. The 2024 weighted average diluted share guidance of 1,263 million, down from 1,291 million in 2023, reflects this kind of buyback activity.
What do the non-GAAP adjustments between GAAP and Adjusted EPS mean for investors?
The main adjustments are amortization of intangible assets, which is about $1.48 to $1.58 per share and largely reflects past acquisitions such as Signify Health and Oak Street Health, plus restructuring, acquisition integration, and real estate optimization charges in 2023. Investors should weigh GAAP EPS of $6.37 to $6.61 for 2023 alongside Adjusted EPS, since the gap is substantial and recurring acquisition-related amortization is a real cost of the company's growth strategy.
04—Continue